These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 34791160)

  • 1. Long-term outcome of targeted therapy of underlying conditions in patients with early persistent atrial fibrillation and heart failure: data of the RACE 3 trial.
    Nguyen BO; Crijns HJGM; Tijssen JGP; Geelhoed B; Hobbelt AH; Hemels MEW; Mol WJM; Weijs B; Alings M; Smit MD; Tieleman RG; Tukkie R; Van Veldhuisen DJ; Van Gelder IC; Rienstra M;
    Europace; 2022 Jul; 24(6):910-920. PubMed ID: 34791160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial.
    Rienstra M; Hobbelt AH; Alings M; Tijssen JGP; Smit MD; Brügemann J; Geelhoed B; Tieleman RG; Hillege HL; Tukkie R; Van Veldhuisen DJ; Crijns HJGM; Van Gelder IC;
    Eur Heart J; 2018 Aug; 39(32):2987-2996. PubMed ID: 29401239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapy of underlying conditions improves quality of life in patients with persistent atrial fibrillation: results of the RACE 3 study.
    De With RR; Rienstra M; Smit MD; Weijs B; Zwartkruis VW; Hobbelt AH; Alings M; Tijssen JGP; Brügemann J; Geelhoed B; Hillege HL; Tukkie R; Hemels ME; Tieleman RG; Ranchor AV; Van Veldhuisen DJ; Crijns HJGM; Van Gelder IC
    Europace; 2019 Apr; 21(4):563-571. PubMed ID: 30629160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiarrhythmic drugs in patients with early persistent atrial fibrillation and heart failure: results of the RACE 3 study.
    Al-Jazairi MIH; Nguyen BO; De With RR; Smit MD; Weijs B; Hobbelt AH; Alings M; Tijssen JGP; Geelhoed B; Hillege HL; Tieleman RG; Van Veldhuisen DJ; Crijns HJGM; Van Gelder IC; Blaauw Y; Rienstra M;
    Europace; 2021 Sep; 23(9):1359-1368. PubMed ID: 33899093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
    Martin N; Manoharan K; Davies C; Lumbers RT
    Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upstream therapy for atrial fibrillation in heart failure.
    Goette A
    Heart Fail Clin; 2013 Oct; 9(4):417-25, viii. PubMed ID: 24054475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation: A Report From the GARFIELD-AF Registry.
    Corbalan R; Bassand JP; Illingworth L; Ambrosio G; Camm AJ; Fitzmaurice DA; Fox KAA; Goldhaber SZ; Goto S; Haas S; Kayani G; Mantovani LG; Misselwitz F; Pieper KS; Turpie AGG; Verheugt FWA; Kakkar AK;
    JAMA Cardiol; 2019 Jun; 4(6):526-548. PubMed ID: 31066873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention.
    Savelieva I; Kakouros N; Kourliouros A; Camm AJ
    Europace; 2011 Mar; 13(3):308-28. PubMed ID: 21345926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.
    Teng TK; Tromp J; Tay WT; Anand I; Ouwerkerk W; Chopra V; Wander GS; Yap JJ; MacDonald MR; Xu CF; Chia YM; Shimizu W; ; Richards AM; Voors A; Lam CS
    Lancet Glob Health; 2018 Sep; 6(9):e1008-e1018. PubMed ID: 30103979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of statins and antihypertensive medications in relation to risk of long-standing persistent atrial fibrillation.
    Thacker EL; Jensen PN; Psaty BM; McKnight B; Longstreth WT; Dublin S; Newton KM; Smith NL; Siscovick DS; Heckbert SR
    Ann Pharmacother; 2015 Apr; 49(4):378-86. PubMed ID: 25628466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials.
    Vaduganathan M; Claggett BL; Jhund PS; Cunningham JW; Pedro Ferreira J; Zannad F; Packer M; Fonarow GC; McMurray JJV; Solomon SD
    Lancet; 2020 Jul; 396(10244):121-128. PubMed ID: 32446323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy of potassium canreonate-canrenone in sinus rhythm restoration among patients with atrial fibrillation - a protocol of a pilot, randomized, double -blind, placebo-controlled study (CANREN-AF trial).
    Dąbrowski R; Syska P; Mączyńska J; Farkowski M; Sawicki S; Kubaszek-Kornatowska A; Michałek P; Kowalik I; Szwed H; Hryniewiecki T
    Trials; 2020 May; 21(1):397. PubMed ID: 32398047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of eplerenone on maintenance of sinus rhythm after catheter ablation in patients with long-standing persistent atrial fibrillation.
    Ito Y; Yamasaki H; Naruse Y; Yoshida K; Kaneshiro T; Murakoshi N; Igarashi M; Kuroki K; Machino T; Xu D; Kunugita F; Sekiguchi Y; Sato A; Tada H; Aonuma K
    Am J Cardiol; 2013 Apr; 111(7):1012-8. PubMed ID: 23340033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
    Martin N; Manoharan K; Thomas J; Davies C; Lumbers RT
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012721. PubMed ID: 29952095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment and prevention of atrial fibrillation with non-antiarrhythmic pharmacologic therapy.
    Lozano HF; Conde CA; Florin T; Lamas GA
    Heart Rhythm; 2005 Sep; 2(9):1000-7. PubMed ID: 16171759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure Trial.
    O'Meara E; Khairy P; Blanchet MC; de Denus S; Pedersen OD; Levesque S; Talajic M; Ducharme A; White M; Racine N; Rouleau JL; Tardif JC; Roy D;
    Circ Heart Fail; 2012 Sep; 5(5):586-93. PubMed ID: 22798522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Upstream therapy of atrial fibrillation in patients with heart failure].
    Alboni P; Gianfranchi L; Pacchioni F
    G Ital Cardiol (Rome); 2009 Sep; 10(9):566-71. PubMed ID: 19891248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure: background, aims and design of the RACE 3 study.
    Alings M; Smit MD; Moes ML; Crijns HJ; Tijssen JG; Brügemann J; Hillege HL; Lane DA; Lip GY; Smeets JR; Tieleman RG; Tukkie R; Willems FF; Vermond RA; Van Veldhuisen DJ; Van Gelder IC
    Neth Heart J; 2013 Jul; 21(7-8):354-63. PubMed ID: 23700039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation.
    Richter B; Derntl M; Marx M; Lercher P; Gössinger HD
    Am Heart J; 2007 Jan; 153(1):113-9. PubMed ID: 17174648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Adherence to Guideline for Heart Failure with Reduced Ejection Fraction in Heart Failure with Preserved Ejection Fraction and with or without Atrial Fibrillation.
    Ahn MS; Yoo BS; Son JW; Park YJ; Lee HY; Jeon ES; Kang SM; Choi DJ; Kim KH; Cho MC; Kim SY; Kang DR; Go TH
    J Korean Med Sci; 2021 Oct; 36(40):e252. PubMed ID: 34664798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.